Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Adults with perianal Crohn\u2019s disease who are anti-TNF-naive and have shorter disease duration benefited most from upadacitinib. Nearly half (45.5%) of patients achieved clinical response at 6 months. Upadacitinib improved fistula outcomes in adults with perianal Crohn\u2019s disease, with the strongest benefit reported among those who had no history of tumor necrosis factor inhibition use and those treated earlier in their disease course. Retrospective cohort study data published in Clinical Gastroenterology and Hepatology showed that 45.5% of patients achieved clinical response and 39.4% achieved clinical remission.
Data derived from\u00a0Devi J, et al. Clin Gastroenterol Hepatol.2026;doi:10.1016\/j.cgh.2026.05.003.
Parakkal Deepak \u201cI don\u2019t recall any prior studies that have shown a relationship between duration of perianal disease in response to this treatment,\u201d Parakkal Deepak, MBBS, MS, co-director of the IBD Center and director of clinical and translational research in the division of gastroenterology at Washington University School of Medicine in St. Louis, told Healio. \u201cIn Crohn\u2019s disease, people have shown that longer disease duration tends to respond less well to any advanced therapy. Here we are showing this [result] with upadacitinib, but we are showing it specifically in the perianal Crohn\u2019s disease cohort, which is novel.\u201d Post-hoc analysis of phase 3 trials have demonstrated efficacy of upadacitinib (Rinvoq, AbbVie) in perianal Crohn\u2019s disease, but data are lacking on real-world effectiveness, according to study background. Efficacy data were also lacking in MRI endpoints. For that reason, Deepak and colleagues conducted a multicenter, retrospective cohort study evaluating clinical and radiologic outcomes among patients with perianal Crohn\u2019s disease who received upadacitinib. \u201cWith Crohn\u2019s disease, we often talk about a 40% to 50% therapeutic ceiling with most medications,\u201d Deepak said. \u201cThat therapeutic ceiling is even lower in patients with refractory condition of perianal Crohn\u2019s disease, broadly around 30% to 35%. \u201cBecause it\u2019s a smaller subset of patients with Crohn\u2019s disease, you need strength in numbers across multiple sites to answer questions in this area,\u201d he added. The analysis included 125 adults (56% men; median age, 33 years; 50.4% white) with active perianal Crohn\u2019s disease who received treatment with upadacitinib at 10 centers across North America. More than three-quarters (77.4%) had a history of anti-TNF use and 48% had complex fistulas. Clinical response, defined as at least a 3-point reduction in Perianal Disease Activity Index (PDAI) score, served as the primary outcome. Secondary outcomes included clinical remission, defined as no greater than a 4-point reduction in PDAI score with either a 3-point decrease or no worsening from baseline; at least a 50% reduction in C-reactive protein; pelvic MRI outcomes; and rates of hospitalization, antibiotic use and perianal Crohn\u2019s disease-related surgery. The majority of patients received 45 mg upadacitinib at induction (98%), with some patients receiving 15 mg (1%) or 30 mg (1%). The induction phase lasted 12 weeks for most patients (93%), with others undergoing an 8-week induction. Nearly all patients (99%) transitioned to a 30 mg maintenance phase. At first follow-up (median, 6 months), data showed 45.5% of patients achieved clinical response. Researchers observed significantly higher clinical response in patients with no history of anti-TNF use (66.7% vs. 33.3%; HR = 0.38; 95% CI, 0.22-0.66) and those with shorter disease duration (54.7% vs. 33.3%), defined as less than 2 years. Significant improvements also were observed across multiple PDAI domains, mostly discharge (59.6%), pain and restriction of activities (56.6%), degree of induration (44.4%) and restriction of sexual activity (36.4%), as well as type of perianal disease (16.2%). A total of 39.4% of patients achieved clinical remission, 13.1% underwent perianal surgery and 5.1% were hospitalized. About a fifth (20.2%) achieved CRP reduction of more than 50%. Of 78 patients with follow-up pelvic MRI data, 55.1% had radiologic improvement and 11.5% achieved complete healing. The study had limitations, including its observational design, potential bias, limited long-term follow-up and availability of pelvic MRI data for slightly more than half of patients. Additionally, researchers noted that the lack of a control group did not allow for effectiveness comparisons. \u201cThe data at the moment are still somewhat limited in terms of the duration of follow-up, but I\u2019ll still say that we were somewhat surprised at seeing a 45% clinical response,\u201d Deepak said. \u201cOn the MRI data, we actually showed that about 11.5% of patients were completely healed. Those are important data, we believe, which guides care moving forward.\u201d For more information: Parakkal Deepak, MBBS, MS, professor of medicine, co-director of the IBD center and director of clinical and translational research in the division of gastroenterology at Washington University School of Medicine in St. Louis, can be reached at deepak.parakkal@wustl.edu. Published by: Sources\/Disclosures Source: Devi J, et al. Clin Gastroenterol Hepatol.2026;doi:10.1016\/j.cgh.2026.05.003.
Disclosures:
Deepak reports research support from and\/or consulting roles with AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, CorEvitas, Fresenius Kabi, Iterative scopes, Janssen, Landos Pharmaceuticals, Pfizer, Prometheus Biosciences, Roche\/Genentech, Scipher Medicine, Takeda Pharmaceuticals and Teva Pharmaceuticals. Please see the study for all other authors\u2019 relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
PubMed, enrolling\/recruiting trials, guidelines
Clinical Guidance, Healio CME, FDA news
Healio’s exclusive daily news coverage of clinical data
Learn more
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link<\/p>\n","protected":false},"author":1,"featured_media":3006,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3005","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/3005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3005"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/3005\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/3006"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Healio](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hgld\/healio_gastro.svg?la=en&h=40&w=152&hash=2C654A538F2E250F5183D42A89FE0EC0\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n